Wang Shaofeng, Liu Wenhua
Department of Orthopedics, The Affiliated Hospital of Weifang Medical College, Weifang, Shandong 261031, P.R. China.
Mol Med Rep. 2016 Sep;14(3):2143-9. doi: 10.3892/mmr.2016.5498. Epub 2016 Jul 11.
Multiple myeloma (MM) is a type of cancer characterized by the excessive proliferation of malignant plasma cells. In China, the incidence of MM has been increasing annually. Paeoniflorin exerts numerous functions, including coronary vessel expansion, and anti‑inflammation and anticancer activities. The present study aimed to investigate the effects of paeoniflorin on the proliferation and apoptosis of SKO‑007 MM cells, via its effects on the regulation of matrix metalloproteinase‑2 (MMP‑2) and microRNA (miR)‑29b. In the present study, an MTT assay was used to analyze the proliferation of SKO‑007 cells treated with paeoniflorin. Annexin V‑fluorescein isothiocyanate/propidium iodide apoptosis and caspase‑3 activation assays were used to detect the levels of cellular apoptosis. The expression levels of MMP‑2 and miR‑29b were detected using gelatin zymography and quantitative‑polymerase chain reaction, respectively. In addition, miR‑29b and anti‑miR‑29b plasmids were transfected into SKO‑007 cells, and the effects of paeoniflorin on cell proliferation and apoptosis were subsequently detected. The results of the present in vitro studies demonstrated that paeoniflorin was able to inhibit the proliferation of SKO‑007 cells in a dose‑ and time‑dependent manner. Furthermore, paeoniflorin effectively increased cell apoptosis, and augmented the activation of caspase‑3 and caspase‑9 in the SKO‑007 cells. The expression levels of MMP‑2 were suppressed following treatment of the SKO‑007 cells with paeoniflorin. In addition, paeoniflorin was able to induce the expression of miR‑29b. Notably, the results of the present study indicated that miR‑29b expression may control the expression of MMP‑2 in SKO‑007 cells. In conclusion, the present study demonstrated that paeoniflorin was able to inhibit cell proliferation and promote apoptosis of MM cells by suppressing the expression of MMP‑2, via the upregulation of miR‑29b.
多发性骨髓瘤（MM）是一种以恶性浆细胞过度增殖为特征的癌症。在中国，MM的发病率逐年上升。芍药苷具有多种功能，包括扩张冠状动脉以及抗炎和抗癌活性。本研究旨在通过芍药苷对基质金属蛋白酶-2（MMP-2）和微小RNA（miR）-29b的调控作用，探讨其对SKO-007骨髓瘤细胞增殖和凋亡的影响。在本研究中，采用MTT法分析经芍药苷处理的SKO-007细胞的增殖情况。采用膜联蛋白V-异硫氰酸荧光素/碘化丙啶凋亡检测法和半胱天冬酶-3激活检测法检测细胞凋亡水平。分别采用明胶酶谱法和定量聚合酶链反应检测MMP-2和miR-29b的表达水平。此外，将miR-29b和抗miR-29b质粒转染到SKO-007细胞中，随后检测芍药苷对细胞增殖和凋亡的影响。本体外研究结果表明，芍药苷能够以剂量和时间依赖性方式抑制SKO-007细胞的增殖。此外，芍药苷有效增加细胞凋亡，并增强SKO-007细胞中半胱天冬酶-3和半胱天冬酶-9的激活。用芍药苷处理SKO-007细胞后，MMP-2的表达水平受到抑制。此外，芍药苷能够诱导miR-29b的表达。值得注意的是，本研究结果表明，miR-29b的表达可能控制SKO-007细胞中MMP-2的表达。总之，本研究表明，芍药苷能够通过上调miR-29b抑制MMP-2的表达，从而抑制骨髓瘤细胞的增殖并促进其凋亡。
